These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30633968)

  • 1. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
    Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
    Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.
    Xu Y; Zhou D; Wang Y; Li J; Wang M; Lu J; Zhang H
    Food Chem Toxicol; 2016 Aug; 94():138-47. PubMed ID: 27259818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
    Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
    Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
    Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
    Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
    J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
    Dennison J; Puri A; Warrington S; Endo T; Adeloye T; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):860-870. PubMed ID: 29870591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.
    Korzekwa K
    Methods Mol Biol; 2021; 2342():685-693. PubMed ID: 34272712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
    Iga K; Kiriyama A
    Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
    Backman JT; Filppula AM; Niemi M; Neuvonen PJ
    Pharmacol Rev; 2016 Jan; 68(1):168-241. PubMed ID: 26721703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
    Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
    Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.
    Xiao Q; Tang L; Xu R; Qian W; Yang J
    Biopharm Drug Dispos; 2015 Dec; 36(9):603-12. PubMed ID: 26296069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
    Itkonen MK; Tornio A; Filppula AM; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2018 Sep; 104(3):495-504. PubMed ID: 29171020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
    Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
    Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
    Jani RH; Kansagra K; Jain MR; Patel H
    Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.